PE20010204A1 - Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidrofuran-3-carboxilicos como inhibidores de metaloproteasas y reprolisina - Google Patents

Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidrofuran-3-carboxilicos como inhibidores de metaloproteasas y reprolisina

Info

Publication number
PE20010204A1
PE20010204A1 PE2000000510A PE0005102000A PE20010204A1 PE 20010204 A1 PE20010204 A1 PE 20010204A1 PE 2000000510 A PE2000000510 A PE 2000000510A PE 0005102000 A PE0005102000 A PE 0005102000A PE 20010204 A1 PE20010204 A1 PE 20010204A1
Authority
PE
Peru
Prior art keywords
cancer
metaloproteases
arylsulfonylamine
reprolysin
hydroxyamides
Prior art date
Application number
PE2000000510A
Other languages
English (en)
Inventor
Lawrence Alan Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010204A1 publication Critical patent/PE20010204A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A DERIVADOS HIDROXIAMIDA DE ACIDOS 3-(ARILSULFONILAMINO)-TETRAHIDROFURAN-3-CARBOXILICOS, DONDE: R1 ES H, OH, ALQUILO C1-6, ALCOXI C1-C6, (ALCOXI C1-C6)(ALCOXI C1-C6, ENTRE OTROS; R2 ES H, OH, ALQUILO C1-C6, ALCOXI C1-C6, ALCOXI C1-C6-ALCOXI C1-C6, ENTRE OTROS; CON LA CONDICION QUE CUANDO UNO DE R1 O R2 ES OH, EL OTRO NO ES OH, ALCOXI C1-C6, ALCOXI C1-C6-ALCOXI C1-C6, ENTRE OTROS; O R1 JUNTO CON R2 FORMAN UN CARBONILO; Q ES ALQUILO C1-C6, ARILO C6-C10, HETEROARILO C2-C9, (ARILOXI C6-C10)(ALQUILO C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS HIDROXIAMIDA DEL ACIDO 3-[4-(4-FLUOROFENOXI)BENCENO-SULFONILAMINO]TETRAHIDROFURAN-3-CARBOXILICO, HIDROXIAMIDA DEL ACIDO 3-[4-(4-CLOROFENOXI)BENCENOSULNILAMMINO]TETRAHIDROFURAN-3-CARBOXILICO. EL COMPUESTO I ES UN INHIBIDOR DE LA REPROLISINA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ARTRITIS, ENFERMEDAD INFLAMATORIA DEL INTESTINO, ENFERMEDAD DE CROHN, ENFISEMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2000000510A 1999-05-28 2000-05-26 Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidrofuran-3-carboxilicos como inhibidores de metaloproteasas y reprolisina PE20010204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13667799P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
PE20010204A1 true PE20010204A1 (es) 2001-03-05

Family

ID=22473882

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000510A PE20010204A1 (es) 1999-05-28 2000-05-26 Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidrofuran-3-carboxilicos como inhibidores de metaloproteasas y reprolisina

Country Status (19)

Country Link
US (1) US6342521B1 (es)
EP (1) EP1181285B1 (es)
JP (1) JP3828748B2 (es)
AT (1) ATE251618T1 (es)
AU (1) AU4309800A (es)
BR (1) BR0011538A (es)
CA (1) CA2375513C (es)
DE (1) DE60005818T2 (es)
DK (1) DK1181285T3 (es)
ES (1) ES2203456T3 (es)
GT (1) GT200000084A (es)
HN (1) HN2000000052A (es)
MA (1) MA26737A1 (es)
MX (1) MXPA01012266A (es)
PE (1) PE20010204A1 (es)
PT (1) PT1181285E (es)
TN (1) TNSN00114A1 (es)
UY (1) UY26169A1 (es)
WO (1) WO2000073294A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP4343373B2 (ja) * 2000-01-14 2009-10-14 富士フイルム株式会社 写真サービスシステム及びデジタルカメラ
KR20020081465A (ko) 2000-03-21 2002-10-26 더 프록터 앤드 갬블 캄파니 헤테로시클릭 측쇄 함유, ｎ-치환된 메탈로프로테아제저해제
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
WO2001070690A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
US6548539B1 (en) * 2001-03-05 2003-04-15 Avalon Pharmaceuticals Agents for regulation of colon cancer gene expression
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
PL334846A1 (en) * 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
PT977733E (pt) * 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
EP0925289A1 (en) * 1997-07-10 1999-06-30 PHARMACIA & UPJOHN S.p.A. Matrix metalloproteinase inhibitors
JP2001513484A (ja) * 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤

Also Published As

Publication number Publication date
JP2003500484A (ja) 2003-01-07
AU4309800A (en) 2000-12-18
DE60005818D1 (de) 2003-11-13
WO2000073294A3 (en) 2001-03-29
MA26737A1 (fr) 2004-12-20
UY26169A1 (es) 2000-12-29
ATE251618T1 (de) 2003-10-15
BR0011538A (pt) 2002-02-26
CA2375513C (en) 2006-11-28
HN2000000052A (es) 2001-02-02
DK1181285T3 (da) 2004-01-26
WO2000073294A2 (en) 2000-12-07
MXPA01012266A (es) 2002-07-30
GT200000084A (es) 2001-11-17
PT1181285E (pt) 2004-01-30
JP3828748B2 (ja) 2006-10-04
EP1181285A2 (en) 2002-02-27
EP1181285B1 (en) 2003-10-08
US6342521B1 (en) 2002-01-29
ES2203456T3 (es) 2004-04-16
TNSN00114A1 (fr) 2002-05-30
DE60005818T2 (de) 2004-05-06
CA2375513A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
UY25992A1 (es) Procedimiento para preparar inhibidores de tace (enzima conversora del factor alfa de necrosis tumoral)
EA199900641A1 (ru) Производные арилсульфонилгидроксамовой кислоты
AP9801174A0 (en) Cyclic sulfone derivatives.
TR200002951T2 (tr) (4-Arilsülfonilamino)-tetrahidropiran-4-karboksilik asit hidroksamitler
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
BR0207378A (pt) Tratamento de câncer
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
HK1060067A1 (en) Compositions for antitumour treatment containing ecteinascidin 743
CA2367704A1 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
PE20010204A1 (es) Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidrofuran-3-carboxilicos como inhibidores de metaloproteasas y reprolisina
PE20010170A1 (es) Hidroxiamidas de acidos 3-(arilsulfonilamino)-tetrahidropiran-3-carboxilicos como inhibidores de metaloproteasas
EP2286826A3 (en) Treatment of tumor metastase and cancer

Legal Events

Date Code Title Description
FD Application declared void or lapsed